Evidence map›Paper›PMID 25838984›Full record

ArticleTissue barriers2015

NF-κB inhibitors impair lung epithelial tight junctions in the absence of inflammation.

Christina Ward, Barbara Schlingmann, Arlene A Stecenko, David M Guidot, Michael Koval

Open access · bronzeAbstract read
In one paragraph

Article in Tissue barriers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Non-typeableEuropean respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Christina WardPulmonary Division; Department of Medicine; Emory University School of Medicine ; Atlanta, GA USA.
Barbara SchlingmannPulmonary Division; Department of Medicine; Emory University School of Medicine ; Atlanta, GA USA.
Arlene A StecenkoDepartment of Pediatrics; Emory University School of Medicine ; Atlanta, GA USA.
David M GuidotPulmonary Division; Department of Medicine; Emory University School of Medicine ; Atlanta, GA USA.
Michael KovalPulmonary Division; Department of Medicine; Emory University School of Medicine ; Atlanta, GA USA ; Department of Cell Biology; Emory University School of Medicine ; Atlanta, GA USA.
Pulmonary Associates · USEmory University · US

Funding

THE ROLE OF TGFB IN ETHANOL MEDIATED LUNG INJURYP50AA013757 · NIAAA · EMORY UNIVERSITY · PI MARTIN, GREGORY S · 2003 to 2013
$15.7M
Institutional Training Grant in Alcohol ResearchT32AA013528 · NIAAA · EMORY UNIVERSITY · PI GUIDOT, DAVID MARSHALL · 2002 to 2011
$3.2M
C/EBP Beta Regulation of Lung InflammationR01HL070891 · NHLBI · EMORY UNIVERSITY · PI STECENKO, ARLENE A · 2004 to 2008
$1.9M
Molecular regulation of pulmonary tight junctionsR01HL116958 · NHLBI · EMORY UNIVERSITY · PI KOVAL, MICHAEL H. · 2013 to 2016
$1.5M
NHLBI NIH HHS R01 HL070891NHLBI NIH HHS R01 HL116958NIAAA NIH HHS P50 AA013757NIAAA NIH HHS T32 AA013528
6 · The paper itself

Abstract

NF-κB (p50/p65) is the best characterized transcription factor known to regulate cell responses to inflammation. However, NF-κB is also constitutively expressed. We used inhibitors of the classical NF-κB signaling pathway to determine whether this transcription factor has a role in regulating alveolar epithelial tight junctions. Primary rat type II alveolar epithelial cells were isolated and cultured on Transwell permeable supports coated with collagen for 5 d to generate a model type I cell monolayer. Treatment of alveolar epithelial monolayers overnight with one of 2 different IκB kinase inhibitors (BAY 11-7082 or BMS-345541) resulted in a dose-dependent decrease in TER at concentrations that did not affect cell viability. In response to BMS-345541 treatment there was an increase in total claudin-4 and claudin-5 along with a decrease in claudin-18, as determined by immunoblot. However, there was little effect on the total amount of cell-associated claudin-7, occludin, junctional adhesion molecule A (JAM-A), zonula occludens (ZO)-1 or ZO-2. Moreover, treatment with BMS-345541 resulted in altered tight junction morphology as assessed by immunofluorescence microscopy. Cells treated with BMS-345541 had an increase in claudin-18 containing projections emanating from tight junctions ("spikes") that were less prominent in control cells. There also were several areas of cell-cell contact which lacked ZO-1 and ZO-2 localization as well as rearrangements to the actin cytoskeleton in response to BMS-345541. Consistent with an anti-inflammatory effect, BMS-345541 antagonized the deleterious effects of lipopolysaccharide (LPS) on alveolar epithelial barrier function. However, BMS-345541 also inhibited the ability of GM-CSF to increase alveolar epithelial TER. These data suggest a dual role for NF-κB in regulating alveolar barrier function and that constitutive NF-κB function is required for the integrity of alveolar epithelial tight junctions.

Indexed as

alveolusARDS, Acute Respiratory Distress SyndromeclaudinGM-CSF, Granulocyte Macrophage Colony Stimulating FactorIL, interleukinIκB, Inhibitor of κBJAM-A, junctional adhesion molecule ALPS, lipolysaccharidelung barrierNF-κB, nuclear factor kappa-light-chain-enhancer of activated B cellsPBS, phosphate buffered salineTER, transepithelial resistancetight junctionTNF, Tumor Necrosis FactorZO, zonula occludens

Identifiers

PMID25838984
PMCPMC4372020
OpenAlexW2091263766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.